Nyxoah Q3 net loss narrows 24% to EUR 17.83 million
NYXH•Nyxoah's third-quarter net loss narrowed 24% year over year to €17.83 million, while revenue rose to €9.17 million. The company said its ACCCESS study met primary safety and efficacy endpoints and expects sales to continue ramping up, primarily in the United States, during 2026.
1. Quarterly results and outlook
Nyxoah reported a third-quarter 2026 net loss of €17.83 million, down 24% year over year, and revenue of €9.17 million. Selling, general and administrative expenses for the first nine months rose 31% to €47.01 million, driven by higher U.S. commercialization and intellectual property litigation costs. The ACCCESS study met its primary safety and efficacy endpoints, and preparations are underway for an FDA submission to expand Genio's indication. Nyxoah expects sales to continue ramping up primarily in the United States during 2026.
